Crisnatol

Drug Profile

Crisnatol

Alternative Names: 770U82; BW 770; BW 77OU82; BW A770U; Crisnatol mesylate

Latest Information Update: 17 Jun 2002

Price : $50

At a glance

  • Originator Cancer Therapy and Research Center; Sanofi Winthrop
  • Developer ILEX Oncology Inc
  • Class Antineoplastics; Chrysenes; Propylene glycols; Small molecules
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Glioma; Solid tumours

Most Recent Events

  • 17 Jun 2002 Discontinued - Phase-I for Solid tumours in USA (IV-infusion)
  • 17 Jun 2002 Discontinued - Phase-III for Glioma in USA (unspecified route)
  • 23 Feb 2000 A study has been added to the therapeutic trials, adverse events and pharmacokinetics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top